Compare Eos Energy Enterprises Inc (EOSE) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eos Energy Enterprises Inc vs Organon & Co. Common Stock — how do they compare? Eos Energy Enterprises Inc trades at $1.92 (market cap $846.69M), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 4.3× Eos Energy Enterprises Inc's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eos Energy Enterprises Inc for 17 Days and Organon & Co. Common Stock for 0 Days on average.
| EOSE | OGN | |
|---|---|---|
Market Cap | $846.69M | $3.62B |
Volume | 19,531,326 | 2,892,999 |
Sector | Industrials | Health |
52-Week High | $19.19 | $13.81 |
52-Week Low | $1.95 | $5.70 |
Typical Hold Time | 17 Days | 0 Days |
Enterprise Value | $1.18B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $2.32, down 2.93% today, with bearish technical signals from moving averages despite oversold RSI readings. The company shows explosive revenue growth (from $114M in 2025 to $214M in 2026) but remains deeply unprofitable with negative gross margins and net losses. Recent catalysts include a $87M DOE loan advance and a Google partnership for a West Virginia energy project, driving positive media coverage.
The stock presents high-risk speculation with Wall Street analysts maintaining a cautious 'Hold' consensus (63.64%) despite a $7.10 price target implying 206% upside. Investment appeal hinges on EOSE scaling production and achieving profitability, but substantial execution risks and cash burn require careful monitoring. Current valuation at 4.46x sales appears stretched given persistent losses.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
